Subscribe: pubmed: BMT[Jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0rkpg7psB96kXSn8rHgLXj86RUVpfN48_gOyRQErBE5
Preview: pubmed: BMT[Jour]

pubmed: BMT[Jour]



NCBI: db=pubmed; Term="Bone marrow transplantation"[Jour]



 



Early hepatitis E infection in an unrelated hematopoietic progenitor stem cell donor.
Related Articles

Early hepatitis E infection in an unrelated hematopoietic progenitor stem cell donor.

Bone Marrow Transplant. 2017 Jul 17;:

Authors: O'Donghaile D, O'Flaherty N, Field S

PMID: 28714948 [PubMed - as supplied by publisher]




Long-term systolic function in children and young adults after hematopoietic stem cell transplant.
Related Articles

Long-term systolic function in children and young adults after hematopoietic stem cell transplant.

Bone Marrow Transplant. 2017 Jul 17;:

Authors: Rotz SJ, Dandoy CE, Taylor MD, Jodele S, Jefferies JL, Lane A, El-Bietar JA, Powell AW, Davies SM, Ryan TD

Abstract
Congestive heart failure and subclinical left ventricular systolic dysfunction (LVSD) affect long-term survivors of hematopoietic stem cell transplant (HSCT). Echocardiographic measurements of global longitudinal and circumferential strain have shown promise in identifying subclinical LVSD in cancer survivors. We analyzed echocardiograms in 95 children and young adults with malignancies or bone marrow failure syndromes performed before HSCT and 1-6 years after HSCT. We additionally measured the biomarkers soluble suppression of tumorigenicity-2 (sST-2) and cardiac troponin-I (cTn-I) in the same children through 49 days post HSCT. Ejection fraction (EF) after HSCT was unchanged from baseline (baseline: z-score -0.73 vs long-term follow up: -0.44, P=0.11). Global longitudinal strain was unchanged from baseline (-20.66 vs -20.74%, P=0.90) as was global circumferential strain (-24.3 vs -23.5%, P=0.32). Levels of sST-2 were elevated at all time points compared with baseline samples and cTn-I was elevated at days 14 and 28. Cardiac biomarkers at any time point did not correlate with long-term follow-up EF. In children and young adult survivors of HSCT, EF was unchanged in the first years after HSCT. Elevation in cardiac biomarkers occurring after HSCT suggest subclinical cardiac injury occurs in many patients and long-term monitoring for LVSD should continue.Bone Marrow Transplantation advance online publication, 17 July 2017; doi:10.1038/bmt.2017.162.

PMID: 28714947 [PubMed - as supplied by publisher]




Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality.
Related Articles

Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality.

Bone Marrow Transplant. 2017 Jul 17;:

Authors: Innes AJ, Mullish BH, Fernando F, Adams G, Marchesi JR, Apperley JF, Brannigan E, Davies F, Pavlů J

PMID: 28714946 [PubMed - as supplied by publisher]




Impact of molecular residual disease post allografting in myelofibrosis patients.
Related Articles

Impact of molecular residual disease post allografting in myelofibrosis patients.

Bone Marrow Transplant. 2017 Jul 17;:

Authors: Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N

Abstract
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI: 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI: 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.Bone Marrow Transplantation advance online publication, 17 July 2017; doi:10.1038/bmt.2017.157.

PMID: 28714945 [PubMed - as supplied by publisher]




Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.
Related Articles

Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.

Bone Marrow Transplant. 2017 Jul 17;:

Authors: Kawamura K, Kanda J, Fuji S, Murata M, Ikegame K, Yoshioka K, Fukuda T, Ozawa Y, Uchida N, Iwato K, Sakura T, Hidaka M, Hashimoto H, Ichinohe T, Atsuta Y, Kanda Y

Abstract
HLA 1-locus-mismatched unrelated donors (1MMUD) have been used in allogeneic hematopoietic stem cell transplantation (allo-HCT) for patients who lack an HLA-matched donor. We retrospectively analyzed 3313 patients with acute leukemia or myelodysplastic syndrome who underwent bone marrow transplantation from an HLA allele-matched unrelated donor (MUD) or 1MMUD between 2009 and 2014. We compared the outcomes of MUD (n=2089) and 1MMUD with antithymocyte globulin (ATG) (1MM-ATG(+); n=109) with those of 1MMUD without ATG (1MM-ATG(-); n=1115). The median total dose of ATG (thymoglobulin) was 2.5 mg/kg (range 1.0-11.0 mg/kg) in the 1MM-ATG(+) group. The rates of grade III-IV acute GvHD, non-relapse mortality (NRM) and overall mortality were significantly lower in the MUD group than in the 1MM-ATG(-) group (hazard ratio (HR) 0.77, P=0.016; HR 0.74; P<0.001; and HR 0.87, P=0.020, respectively). Likewise, the rates of grade III-IV acute GVHD, NRM and overall mortality were significantly lower in the 1MM-ATG(+) group than in the 1MM-ATG(-) group (HR 0.42, P=0.035; HR 0.35, P<0.001; and HR 0.71, P=0.042, respectively). The outcome of allo-HCT from 1MM-ATG(-) was inferior to that of allo-HCT from MUD even in the recent cohort. However, the negative impact of 1MMUD disappeared with the use of low-dose ATG without increasing the risk of relapse.Bone Marrow Transplantation advance online publication, 17 July 2017; doi:10.1038/bmt.2017.153.

PMID: 28714944 [PubMed - as supplied by publisher]




Dengue encephalitis in allogenic hematopoietic stem cell transplantation recipient.
Related Articles

Dengue encephalitis in allogenic hematopoietic stem cell transplantation recipient.

Bone Marrow Transplant. 2017 Jul 17;:

Authors: Barroso KSN, Kaufman J, Brunetta DM, de Carvalho Araújo FM, Barroso-Duarte F

PMID: 28714943 [PubMed - as supplied by publisher]